NCT01947023View on ClinicalTrials.gov

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 27, 2013

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2026

Conditions
Metastatic Thyroid Gland CarcinomaUnresectable Thyroid Gland Carcinoma
Interventions
PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Dabrafenib

Given PO

DRUG

Dabrafenib Mesylate

Given PO

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

Lapatinib

Given PO

DRUG

Lapatinib Ditosylate

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Positron Emission Tomography

Undergo PET

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH